R. Hargreaves

Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.

D. Ross, D. Siegel, J. Butler, 1995, Molecular pharmacology.

Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma.

P. Khan, A. McGown, R. Caffrey, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition.

L. Whitesell, D. LaBarbera, C. L. David, 2008, Journal of medicinal chemistry.

Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones.

L. Amzel, D. Ross, M. Bianchet, 2001, Structure.

A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.

D. Ross, J. Butler, S. Winski, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.

D. Ross, D. Dehn, C. Moody, 2001, Biochemical pharmacology.

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

G. Jayson, M. Ranson, T. Ward, 2005, Clinical Cancer Research.

Design of quinolinedione-based geldanamycin analogues.

L. Whitesell, C. L. David, E. B. Skibo, 2003, Bioorganic & medicinal chemistry letters.